Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)

BACKGROUND: The median age of newly diagnosed patients with non-small cell lung cancer (NSCLC) is 67 years, and one-third of patients are older than 75 years. Elderly patients are more vulnerable to the adverse effects of chemotherapy, and targeted therapy might thus be a relevant alternative. The o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Christos, Chouaid, Hervé, Le Caer, Chrystelle, Locher, Cecile, Dujon, Pascal, Thomas, Jean Bernard, Auliac, Isabelle, Monnet, Alain, Vergnenegre
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2012
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3492214/
https://ncbi.nlm.nih.gov/pubmed/22817667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-301
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars